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ABSTRACT
The cumulative evidence in the past three
decades situates ambulatory blood pressure
monitoring (ABPM) as a central element in
diagnosing and predicting the prognosis of
subjects with hypertension. However, for
various reasons, this diagnostic and prognostic
importance has not been translated in equal
measure into making decisions or guiding
antihypertensive treatment. Mean 24-h,
daytime, and night-time blood pressure
estimates, the occurrence of divergent
phenotypes between clinic measurements, and
ABPM, as well as the main elements that
determine blood pressure variability over 24 h,
especially night-time dipping, are all elements
that in addition to providing evidence for
patient prognosis, can be used to guide
antihypertensive treatment follow-up enabling
greater precision in defining the effect of the
drugs. In recent years, specific indices have been
developed using 24-h monitoring, evaluate the
duration of treatment action, the homogeneity
of the effect over the monitoring period, and its
possible effects on variability. In future
controlled clinical trials on antihypertensive
therapies it is necessary to evaluate the effects
of those treatments on hard endpoints based on
therapy guided by ABPM.
Keywords: Ambulatory blood pressure
monitoring; Antihypertensive agents; Blood
pressure variability; Circadian blood pressure
profile; Hypertension; Morning blood pressure
surge; Morning hypertension; Nocturnal
hypertension
INTRODUCTION
Non-invasive clinic blood pressure (BP)
measurement dates back to the early twentieth
century and corresponds to the invention of the
mercury sphygmomanometer by the Italian
physicist Scipione Riva-Rocci, and the
description of arterial sounds by the Russian
physician Nikolai Korotkoff. Since then,
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changes in the procedure for clinic
measurement have been few and have mostly
been based on the appearance of automatic or
semi-automatic devices that have used a
plethysmographic method instead of the
classical auscultatory method described by
Korotkoff. Part of this change has been
motivated by restrictions on using mercury in
health care devices.
The two ways of measuring out-of-clinic BP,
self-measurement at home and ambulatory BP
monitoring (ABPM), were developed to obtain
BP measurements outside health care settings,
since those settings have a significant influence
on BP in some individuals. Furthermore,
especially in the case of ABPM, obtaining a
higher number of measurements in a period
containing the main sources of BP variability
(activity/rest) provides a more precise
approximation of an individual’s true BP.
ABPM research has been particularly focused
on epidemiological and diagnostic aspects. In
this regard, the main indicators obtained during
the course of ABPM correlate better with an
individual’s organ damage and cardiovascular
prognosis [1–4]. Moreover, regarding diagnostic
aspects, ABPM has enabled two new phenotypes
to be defined, white-coat hypertension (HTN)
and masked HTN, both of great clinical interest
[5, 6].
Applying ABPM to therapeutic assessment
has had less of an impact, both on the part of
the investigators as well as on the part of the
investment made by the sponsors of
antihypertensive drugs and devices. A large
part of this is motivated by the fact that the
regulatory authorities continue to consider
clinic BP measurement as the central element
for approving antihypertensive drugs and
devices. Nevertheless, the BP measurement
indicators obtained using ABPM, the patient
phenotypes during hypertensive treatment,
dipping patterns, and BP variability over 24 h
of monitoring, are of equally high interest when
analyzing the effects of antihypertensive
therapies [7]. Furthermore, using ABPM
enables a single assessment of some aspects of
that treatment, such as the duration of action
by calculating specific indices that evaluate the
duration and the homogeneity of the effect.
This article describes the main indicators,
direct or derived, from monitoring itself or
combined between ABPM and clinic
measurement that may be of interest in
patients during antihypertensive treatment.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by the
author.
MEAN 24-H, DAYTIME,
AND NIGHT-TIME BP ESTIMATORS
The mean 24-h, daytime, and night-time
indicators have classically been the most used
for both the relationship between ambulatory
BP and cardiovascular prognosis, as well as for
assessing the antihypertensive effect of drugs.
Daytime BP, or BP during the period of activity,
was one of the first parameters studied, since it
is considered the closest to in-office BP. The
current guidelines for diagnosing and treating
HTN from the National Institute for Health and
Care Excellence (NICE) of the British
Government advises practicing ABPM during
the day to confirm the HTN diagnosis when the
clinic figures are high [8]. Daytime BP has also
been the first used to assess the ‘‘white-coat’’
effect. In the first analyses of the Spanish ABPM
Registry, up to 30% of patients without
treatment [9, 10] and nearly 35% of those
treated with clinic BP figures greater than or
equal to 140/90 mmHg [11] presented normal
daytime BP figures (below 135/85 mmHg).
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One study has used daytime BP to guide
antihypertensive treatment adjustment and
monitoring in comparison with clinic BP [12].
Thus, patients with a clinic diastolic BP greater
than or equal to 95 mmHg were randomized to
using daytime BP or clinic BP to guide treatment
adjustments. Upon ending the study, the
daytime BP-guided monitoring was associated
with a lower use of antihypertensive drugs; with
no differences observed in the organ damage
measured using the degree of left ventricular
hypertrophy.
The mean BP of all measurements made over
24 h of monitoring is considered to be the one
that provides better information. A larger
number of measurements are included in its
calculation. As such, it is less affected by
sporadic situations that may arise during the
day or night or by sporadic errors. It takes into
account daytime activity, work, and the
changes in pressure caused by those activities,
as well as rest and the quality of it, and the
night-time pressure dip. Its relationship with
cardiovascular prognosis, as well as the presence
and severity of organ damage, are clearly better
than clinic pressure. From a therapeutic point of
view, several meta-analyses have evaluated the
correlation between the decrease in clinic BP or
24-h BP induced by antihypertensive treatment.
Thus, in one of them that included 44 studies
with more than 5000 patients, the mean
decreases in clinic BP were 19/10 mmHg, while
those corresponding to the 24-h figures were
13/8 mmHg. The percentage of 24-h BP
reductions compared to clinic BP was 65% and
81%, respectively, for systolic and diastolic BP
[13].
Another conclusion reached in that meta-
analysis was that the definitions of responders
and patients achieving BP control were not able
to be extrapolated to the values obtained in
24-h ABPM. Thus, the final in-office BP values
(143/90 mmHg) were only slightly better than
the normal values (\140/90 mmHg), suggesting
that a high percentage of patients managed to
achieve BP control. Conversely, the final 24-h
BP values (139/86 mmHg) were clearly above
the limits of normal (\130/80 mmHg),
suggesting that achieving 24-h control was far
below the clinic control achievement. These
results were later confirmed in another meta-
analysis that included studies with clinic
measurement, home measurement, and ABPM.
The BP reduction was greater in the clinic than
at home, and higher at home than in the 24-h
values [14].
Night-time BP measurements have been
progressively acquiring more importance. Of
all the indicators obtained during ABPM, it is
the one that is best correlated with the
prognosis [1–4]. Its main advantage is that it
can be considered the baseline BP (the one that
is specified for tissue perfusion in a state of
rest). In addition, the fact that it is generally
measured at rest gives it higher reproducibility
and less variability, which makes it easier to
correlate it with organ damage and prognosis.
The data from the Spanish ABPM Registry [4],
as well as the various prospective cohort
databases [15], indicate that of all the BP
indicators (clinic, daytime, night-time, and
24-h) it is the one that is best independently
correlated with the prognosis (Fig. 1). The
main disadvantages are that it requires an
exact definition of the rest period, it may be
affected by the presence of a daytime rest (nap)
[16], and it is equally affected by the quality of
sleep [17], especially in patients who
repeatedly wake up during the night or who
have sleep apnea.
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PATIENT PHENOTYPES
Jointly using clinic measurement and ABPM has
resulted in the creation of new patient
categories that have expanded the
hypertensive/normotensive dichotomy. Thus,
the consistency between normal figures in
clinic BP and those obtained through ABPM is
called normotension, whereas the consistency
between high figures in the clinic and ABPM
constitute sustained HTN. The two new types
represent the presence of discrepancies between
both forms of measurement. Thus, high
figures in the office and normal ones in ABPM
constitute the phenotype known as white-coat
HTN or isolated clinic HTN. This category, in
principle, restricted to the diagnosis of patients
without treatment, is also used in patients on
treatment in whom ABPM figures are
controlled, but not those in the clinic. At the
opposite extreme are individuals with normal
clinic BP figures but with high ABPM figures.
This situation is known as masked HTN in
untreated individuals or as masked
uncontrolled hypertension (MUCH) in those
who are on treatment.
Though there is a general consensus that the
presence of masked HTN or MUCH confers a
risk that may be comparable to that of sustained
HTN [18, 19] (possibly from a population
perspective the risk is even greater, given that
the individuals who do not know they belong to
this group are mostly not being treated and
outside of health care oversight), there are still
serious doubts about whether white-coat HTN
carries an increased risk and whether it requires
treatment [20, 21]. In general, longitudinal
studies have observed that individuals with
white-coat HTN present a risk of
cardiovascular events similar to normotensive
individuals, although in some cases, an increase
in cerebrovascular accidents has been detected.
Similarly, its association with organ damage has
been described as similar to that of
normotensive individuals in some studies, or
with a higher prevalence of cardiac or renal
damage in others. In many cases, it is hard to
reach a conclusion since, even with the white-
coat HTN diagnosis, these individuals have
higher ABPM figures than normotensive
individuals and, in addition, a very high
percentage go on to develop sustained HTN in
its progression [22].
The prevalence of these divergent phenotypes
depends in large part on the parameter used to
define them and the study population. In
patients with antihypertensive treatment and
high clinic BP figures, white-coat HTN varies
between 27%, if normality is required in all
periods (daytime, night-time, and 24-h), and
45% if only daytime normality is considered [11]
(Fig. 2). For its part, the prevalence of MUCH in
patients with normal clinic BP figures also varies
Fig. 1 Risk of cardiovascular events (non-fatal myocardial
infarctions, non-fatal strokes, or cardiovascular deaths) in
high-risk patients based on the tertile distribution of nSBP.
The risk increases 32% and 50%, respectively, for the
middle and high tertiles. Data extracted from [4]. nSBP
night-time systolic blood pressure, HR Hazard ratio
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between 24%, if only daytime figures are
considered, and 49% if it is defined based on
elevation in any of the indicators (daytime,
night-time, or 24-h; Fig. 3) [23].
The clinical features that are associated with
these divergent phenotypes are, in the case of
white-coat HTN, old age, the female sex, the
absence of other risk factors such as smoking or
Fig. 2 Prevalence of white-coat hypertension in patients in
the Spanish Ambulatory BP Monitoring Registry with or
without treatment and with clinic BP values greater than or
equal to 140/90 mmHg. The prevalence depends on which
parameter is used (daytime, night-time, or 24-h BP, or the
normalcy all of them). BP Blood pressure, OBP Ofﬁce
blood pressure
Fig. 3 Prevalence of masked hypertension in patients in
the Spanish Ambulatory BP Monitoring Registry with
(right) or without (left) antihypertensive treatment and
normal clinic BP (\140/90 mmHg). The prevalence
depends on which parameter is used (daytime, night-time,
or 24-h BP, or any of them). BP Blood pressure, OBP
Ofﬁce blood pressure
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diabetes, and cardiac or renal organ damage [9,
24]; whereas youth, the male sex, smoking,
diabetes, and the presence of organ damage are
correlated with a higher probability of
presenting masked HTN [23, 25]. Obesity
deserves particular mention, as it seems to be
correlated, albeit weakly, with both white-coat
HTN and masked HTN [9, 11, 23]. The
interpretation is that obesity may be an
element that decreases the accuracy of clinic
measurement and, as such, has an impact not
just on phenotype, but also on discrepancies
between measurements. However, it should be
recognized that these clinical associations,
although significant, have little predictive
ability in individuals and in no case should
substitute ABPM in diagnosing a specific
patient. Other features or the physician’s
intuition should also not have any impact.
Thus, the sensitivity and specificity of the
clinical suspicion related by the physician for
diagnosing white-coat HTN presented very low
values in relation to the definitive diagnosis
made by using ABPM [9].
At this time, there is no absolute consensus
on the need for antihypertensive treatment in
patients with divergent phenotypes. All the
observational studies demonstrate that masked
HTN or MUCH result in a high risk of
developing future cardiovascular events. As
such, it seems logical to think that those
patients are suitable for starting
antihypertensive therapy. Nevertheless, no
study has demonstrated that this treatment
will improve the prognosis in those patients;
therefore, the therapeutic decision is
completely empirical. Even more uncertainties
exist about the follow-up for these patients,
including target figures or regularity of
repeating ABPM [26].
As for subjects with white-coat HTN, as
previously mentioned, there are discrepancies
between the likelihood of having a major
cardiovascular event or not. Moreover,
treatment in those patients, even reducing the
BP figures, seems to have little impact on the BP
figures obtained by ABPM. The current
guidelines recommend antihypertensive
treatment in high-risk patients with known
cardiovascular disease or with hypertensive
organ damage. In the rest, a close follow-up
and early detection of the appearance of
sustained HTN seems to be the best option [27].
DIPPING PATTERNS
The decrease in BP caused by rest and sleep,
usually at night, has a favorable impact on
reducing the pressure burden related to the
organ damage. Almost 40 years ago, it was
described that some patients in whom this
night-time dip was less pronounced (the
threshold has been established at 10% versus
the daytime values) had a worse risk profile and
a higher probability of developing
cardiovascular events and death [28]. In
general, four dipping patterns have been
described based on this night-time decrease.
The most common pattern in the healthy
population is known as the ‘‘dipper’’ pattern
and it represents between a 10% and 20%
decrease from daytime values. The extreme
‘‘dipper’’ pattern exceeds this 20% and, even
though it has been described as associated with
a risk of cerebrovascular accident in the Asian
population, a clearly deleterious effect has not
been demonstrated on the prognosis in
Westerners. Conversely, a decrease below 10%,
known as a ‘‘non-dipper’’ pattern (recently the
term ‘‘reduced dipper’’ has been proposed), or
an increase in BP during rest, known as a ‘‘riser’’
pattern, have both been associated with a worse
prognosis and related with organ damage [28,
29].
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The data from the Spanish ABPM Registry
have allowed us to determine that the
prevalence of these ‘‘deleterious’’ patterns is
very high, approaching 50% of untreated
patients and exceeding this figure in those on
treatment (Fig. 4). Old age, the female sex,
obesity, diabetes, and a history of previous
cardiovascular disease are associated with an
inadequate decrease in both treated and
untreated patients. In treated patients,
increasing the number of drugs also results in
a higher probability of presenting a non-dipper
or riser pattern [30, 31].
The main problem in assessing the dipping
pattern is its association with night-time BP
levels. Both elevated night-time BP as well as
inadequate nocturnal dip have been related
with a worse prognosis. Nevertheless, the fact
remains that both situations are intimately
related, which makes it difficult to separate
their independent effects. A separate assessment
of both phenomena has enabled these
uncertainties to be cleared up. Thus, there
have been patients with inadequate night-time
BP dip who despite everything present normal
night-time BP figures, and by contrast, there
have been patients with night-time HTN but
with a night-time BP dip above 10%. In this
analysis, the non-dipper pattern in the absence
of night-time HTN was associated with the
female sex, impaired kidney function, and a
history of cardiovascular events, whereas night-
time HTN in the presence of a normal pattern
was associated with the male sex, diabetes, and
asymptomatic organ damage
(microalbuminuria and left ventricular
hypertrophy). Obviously the worse risk profile
was observed in patients who presented both
night-time HTN and a non-dipper pattern [32].
MORNING HTN AND MORNING
SURGE
After the sleep-induced night-time BP dip, the
morning surge that accompanies waking is a
physiological phenomenon. However, some
studies have observed that an exaggerated
morning BP surge is associated with a higher
rate of cardiovascular events [33]. The hormone
changes that affect cortisol and catecholamines,
Fig. 4 Distribution of dipping patterns in patients without
hypertensive treatment (left) or with hypertensive treat-
ment (right) included in the Spanish Ambulatory Blood
Pressure Monitoring Registry. The presence of an
inadequate night-time dip (riser or non-dipper pattern) is
around 50% in patients without treatment and exceeds this
ﬁgure in those treated
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the increase in heart rate, and the higher
platelet aggregability that happen in these
morning hours are a rationale to explain this
phenomenon [34].
Another parameter of interest intimately
related to the morning surge is known as
morning HTN, which consists of high BP
figures obtained just after waking. A recent
study in patients being treated for HTN
demonstrated that the BP figures obtained in
the first hour of the morning through self-
measurement had a greater prognostic impact
than clinic BP figures. Values above 145 mmHg
were associated with a higher rate of
cardiovascular events [35].
The main problems that arise when
evaluating the phenomena of the morning
surge and morning HTN are, on one hand,
that most studies have been carried out in a
Japanese population. Data in a Mediterranean
population suggest that the morning surge in
this population is less pronounced than in the
Japanese population (De la Sierra; personal
communication); thus its prognostic impact is
presumably less. On the other hand, morning
surge and morning HTN are influenced not only
by physiological or pathophysiological
circumstances, but also by type of treatment,
its posology, and the duration of action of the
drugs. Thus, if we take into account that most
drugs are administered in the morning, this
morning surge coincides with the end of the
period of the therapeutic window, and therefore
only those drugs with a longer half-life will
significantly reduce these parameters.
Although there are not many comparative
studies, not all antihypertensive drugs ensure
24 h of coverage. Olmesartan and telmisartan
among the angiotensin receptor blockers,
lisinopril among the angiotensin-converting
enzyme inhibitors, amlodipine among the
calcium blockers, and chlorthalidone among
the diuretics are probably the drugs with the
longest duration of antihypertensive effect in
their respective classes. Some others with
shorter coverage times may see that time
extended with pharmaceutical modifications
that slow down their absorption.
BP VARIABILITY
BP is a dynamic parameter that fluctuates based
on several circumstances, some intrinsic and
other extrinsic [36]. Long-term BP variability
may be determined through successive visits.
This variability has a prognostic impact,
especially in predicting cerebrovascular
accidents [37]. ABPM enables short-term
fluctuations to be assessed. Some of these,
caused by the activity/rest rhythm, have
already been mentioned and are part of the
night-time dip patterns. However, pressure
fluctuations within one of these periods
(daytime and especially at night) also have a
prognostic impact. They can be evaluated by
calculating the standard deviation in one of the
periods separately and by using indices that take
into account these deviations, and project the
calculation over the entire 24-h period [36].
In recent years, there has been a growing
interest in assessing the impact of
antihypertensive treatment on this short-term
variability determined by ABPM. Initial studies
have used modifications in the posology of the
drugs (administering part or all of the treatment
at night) and assessed their impact on the
dipping pattern. Thus, it has been
demonstrated that this night-time
administration promotes a larger night-time
dip and, as such, a proportion of non-dipper
or riser patients becomes dippers. In one of
these studies, this phenomenon was associated
with a better cardiovascular prognosis [38].
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THERAPEUTIC INDICES OBTAINED
USING ABPM
In addition to all the above-described
parameters used to assess the effect of
antihypertensive therapy, some mathematical
indices have been developed that combined
potency, duration of action, and homogeneity
of effect. This allows for a better assessment of
the effects of antihypertensive treatment.
The first of these indices is the trough-to-
peak (T/P) ratio. Interest in this ratio appeared
nearly two decades ago and consists of
calculating the ratio between the decrease in
BP obtained in the hours just before the end of
the therapeutic window (with drugs
administered once a day between 22 and 24 h
after administration) and the maximum effect
calculated after several hours (between 4 and
6 h after administration). In theory, the closer it
is to unity, the greater the homogeneity of
effect, suggesting that the residual effect of the
drug is close to its maximum effect. However,
the T/P ratio has two significant problems. The
first is a result of poor reproducibility, caused by
the need to extract short periods of monitoring
from a 24-h ABPM that may be influenced by
external factors. Thus, the peak period or
maximum effect may coincide with a
postprandial rest (nap), which will magnify it,
or with a period of higher physical or mental
activity, which will minimize it. For its part,
calculating the trough effect may coincide with
the last hours of sleep or with waking, both
circumstances that may change it. In addition,
the T/P ratio does not take into account the
magnitude of the antihypertensive effect, so
that minimal decreases in BP in the peak will be
associated with high T/P indices (placebos
usually have a T/P index around 1) [39].
The second index that measures
homogeneity of effect is called the smoothness
index (SI) [40]. It is calculated based on the
hourly reductions in BP, corrected by the
standard deviation of those reductions. Thus,
the greater the magnitude of the hourly
reduction and the smaller the differences
between those reductions (less variability), the
higher the resulting number will be. The higher
the SI value is, the higher the drug potency and
the greater the homogeneity of effect. Some
studies have described an ability of the SI to
predict changes in organ-damage parameters
(left ventricular mass and carotid intima-media
thickness) caused by the treatment [41].
One last index proposed very recently is the
treatment-on-variability index (TOVI),
calculated using the ratio between the 24-h
decrease in BP and the change in the weighted
standard deviation (hourly standard deviation
calculated separately during the daytime and
night-time periods and later weighted based on
the duration of each of those periods) [42]. A
recent study using clinical trial databases with
several monotherapies and one combination
therapy demonstrated a greater effect of the
combination therapy and the amlodipine
monotherapy based on that index, in
comparison with two angiotensin receptor
blockers and one angiotensin-converting
enzyme inhibitor [42].
RESISTANT HTN
Between 10% and 15% of patients with HTN do
not manage to normalize their BP values despite
treatment with 3 or more antihypertensive
drugs. They fall under the category of resistant
HTN [24, 43]. Most of them are referred to a
specialist clinic, and despite extensive
diagnostic work and a search for secondary
causes that explain their high BP, the reason
why the BP values cannot be normalized has
not been explained. These patients have more
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organ damage [44] and a worse prognosis [45]
than other patients with HTN.
In a broad study stemming from patients in
the Spanish ABPM Registry, one-third of 8295
patients who could be categorized as resistant
hypertensive had normal 24-h BP figures, where
resistance was due to a white-coat effect.
Compared with truly resistant hypertensive
patients, the organ damage in these patients
was less and the cardiovascular prognosis better
[24].
The need to demonstrate that the BP values
obtained using ABPM are undoubtedly high in
resistant hypertensive patients was recently
supported by the appearance of more invasive
therapies, such as renal sympathetic
denervation or baroreflex stimulation as a
treatment for patients with resistant HTN [46].
The first studies on renal denervation have
demonstrated a significant decrease in BP that
was not confirmed in the recent SIMPLICITY
HTN-3 study (ClinicalTrials.gov number,
NCT01418261), where patients with resistant
HTN required ABPM confirmation [47].
CONCLUSION
ABPM should be considered the standard
measurement of BP, a starting point for
assessing and treating patients with HTN, as
some recent guidelines recommend [5, 6, 8, 48].
A large body of evidence demonstrating a close
epidemiological relationship between the
indicators obtained using ABPM, organ
damage, and cardiovascular prognosis has not
been followed by an equally significant
translation of the impact of ABPM as a guide
to antihypertensive therapy. It has only been in
recent years where, in part due to scientific
interest and in part due to requirements from
regulatory agencies, the need for assessing the
effects of the primary treatments on 24-h BP has
been emphasized. The consistency of the mean
estimators (24-h, daytime, and night-time BP
figures), the new phenotypes of white-coat HTN
and masked HTN, the importance of the
dipping status and BP variability, and the
appearance of specific indices for treatment
assessment have made it so that ABPM should
today be considered an essential element for
guiding antihypertensive treatment, thereby
enabling a more personalized medicine
adapted to the patient. The main barriers for a
more widespread use of ABPM are related to
several factors including costs and
reimbursement, acceptability and complexity
in the interpretation of some estimators.
However, they can be easily solved. More
validated devices are available in the market
with reduced prices, and the acceptance of
patients and health workers in considering
results as a better guidance for diagnosis and
treatment has considerably increased.
Moreover, different software and website
platforms have developed to provide rapid and
easy reports containing the most important
estimators of clinical validity. Some
experiences in several countries, including
Australia, Ireland, Italy, and Spain have
demonstrated that ABPM could be
implemented in almost all clinical settings,
from primary care to reference units, and even
in community pharmacies. This will improve
HTN management in the very near future.
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